Boland PM, Ebos JML, Attwood K, Mastri M, Fountzilas C, Iyer RV, Banker C, Goey AKL, Bies R, Ma WW, Fakih M. A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer. JNCI Cancer Spectr. 2024;8(3):pkae017.

Article  PubMed  PubMed Central  Google Scholar 

Xu X, Yu Y, Liu M, Liang L, Liu T. Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review. Transl Cancer Res. 2022;11(1):276–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mongiardi MP, Pallini R, D’Alessandris QG, Levi A, Falchetti ML. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness. Expert Rev Mol Med. 2024;2(26): e5.

Article  Google Scholar 

Otsuka H, Fukumoto T, Kiyota N, Takemori C, Jimbo H, Nishigori C. Severe and delayed-onset acneiform eruptions as an adverse reaction to regorafenib. Dermatol Reports. 2022;14(2):9303.

Article  PubMed  PubMed Central  Google Scholar 

Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20(6):849–61.

Article  CAS  PubMed  Google Scholar 

Reid Tony R, Abrouk N, Caroen S, et al. ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer. Clin Colorectal Cancer. 2023;22(1):92–9.

Article  CAS  PubMed  Google Scholar 

Lee V, Parkinson R, Zahurak M, et al. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients. Int J Cancer. 2024;154(10):1794–801.

Article  CAS  PubMed  Google Scholar 

Patel AS, Tenner L, Sarantopoulos J, Morris J, Liu Q, Mendez JA, Curiel T, Michalek J, Mahalingam D. Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC). Br J Cancer. 2022;127(6):1153–61.

Article  Google Scholar 

Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12.

Article  CAS  PubMed  Google Scholar 

Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619–29.

Article  CAS  PubMed  Google Scholar 

Tai CC, Chen WS, Jiang JK, et al. Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. Am J Clin Oncol. 2020;43(1):28–34.

Article  PubMed  Google Scholar 

Yoshino T, Komatsu Y, Yamada Y, et al. Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Invest New Drugs. 2015;33(3):740–50.

Article  CAS  PubMed  Google Scholar 

Sanoff HK, Goldberg RM, Ivanova A, et al. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. Cancer. 2018;124(15):3118–26.

Article  CAS  PubMed  Google Scholar 

Mercier J, Voutsadakis IA. A systematic review and meta-analysis of retrospective series of regorafenib for treatment of metastatic colorectal cancer. Anticancer Res. 2017;37:5925–34.

CAS  PubMed  Google Scholar 

Garcia-Alfonso P, Feliu J, Garcia-Carbonero R, et al. Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer? Clin Transl Oncol. 2016;18:1072–81.

Article  CAS  PubMed  Google Scholar 

Fakih M, Sandhu J, Lim D, et al. Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol. 2023;9(5):627–34.

Article  PubMed  PubMed Central  Google Scholar 

Cytryn SL, Moy RH, Cowzer D, et al. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 2023;24(10):1073–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan T, Wu R, Wang W, et al. Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer. Front Pharmacol. 2023;17(14):1136114.

Article  Google Scholar 

Fakih M, Raghav KPS, Chang DZ, et al. Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. EClinicalMedicine. 2023;6(58):101917.

Article  Google Scholar 

Yan H, Liu J, Zhang Y, et al. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a retrospective cohort study. J Gastrointest Oncol. 2024;15(3):987–1001.

Article  PubMed  PubMed Central  Google Scholar 

RøedSkårderud M, Polk A, KjeldgaardVistisen K, Larsen FO, Nielsen DL. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review. Cancer Treat Rev. 2018;62:61–73.

Article  Google Scholar 

Mercier J, Voutsadakis IA. A Systematic Review and Meta-analysis of Retrospective Series of Regorafenib for Treatment of Metastatic Colorectal Cancer. Anticancer Res. 2017;37(11):5925–34.

CAS  PubMed  Google Scholar 

Kehagias P, Kindt N, Krayem M, et al. Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance. Cells. 2022;11(22):3663.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vitale P, Zanaletti N, Famiglietti V, et al. Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. Clin Colorectal Cancer. 2021;20(3):227–35.

Article  PubMed  Google Scholar 

Yan H, Wu W, Hu Y, Li J, Xu J, Chen X, Xu Z, Yang X, Yang B, He Q, Luo P. Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. Nat Commun. 2023;14(1):2756.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dioca M, O’Connor JM. Optimizing Regorafenib Dosing and Patient Management in Colorectal Cancer in Latin America: Perspectives from Argentina. Oncologist. 2021;26(6):e992–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bekaii-Saab TS, Ou FS, Ahn DH, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(8):1070–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hedayat S, Cascione L, Cunningham D, et al. Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer. Clin Cancer Res. 2024;30(10):2140–59.

Article  CAS  PubMed  Google Scholar 

Lee DW, Lim Y, Kim HP, et al. Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer. Cancer Res Treat. 2023;55(3):927–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim DW, Kim YC, Kovari BP, et al. Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer. Cancers (Basel). 2024;16(3):556.

Article  CAS  PubMed  Google Scholar 

Hedayat S, Cascione L, Cunningham D, et al. Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer. Clin Cancer Res. 2024;30(10):2140–59.

Article